DE60316984D1 - Benzoylsulfonamide als antitumor-mittel - Google Patents
Benzoylsulfonamide als antitumor-mittelInfo
- Publication number
- DE60316984D1 DE60316984D1 DE60316984T DE60316984T DE60316984D1 DE 60316984 D1 DE60316984 D1 DE 60316984D1 DE 60316984 T DE60316984 T DE 60316984T DE 60316984 T DE60316984 T DE 60316984T DE 60316984 D1 DE60316984 D1 DE 60316984D1
- Authority
- DE
- Germany
- Prior art keywords
- antitumor
- benzoylsulfonamide
- medium
- formula
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 3
- PLQIOFZPHAZJAM-UHFFFAOYSA-N oxo(phenyl)methanesulfonamide Chemical compound NS(=O)(=O)C(=O)C1=CC=CC=C1 PLQIOFZPHAZJAM-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
- C07C311/51—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/06—One of the condensed rings being a six-membered aromatic ring the other ring being four-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42889102P | 2002-11-22 | 2002-11-22 | |
| US428891P | 2002-11-22 | ||
| PCT/US2003/035041 WO2004048329A1 (en) | 2002-11-22 | 2003-11-13 | Antitumor benzoylsulfonamides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60316984D1 true DE60316984D1 (de) | 2007-11-29 |
| DE60316984T2 DE60316984T2 (de) | 2008-07-17 |
Family
ID=32393476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60316984T Expired - Fee Related DE60316984T2 (de) | 2002-11-22 | 2003-11-13 | Benzoylsulfonamide als antitumor-mittel |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7282595B2 (de) |
| EP (1) | EP1565438B1 (de) |
| AT (1) | ATE375978T1 (de) |
| AU (1) | AU2003290592A1 (de) |
| DE (1) | DE60316984T2 (de) |
| ES (1) | ES2294342T3 (de) |
| WO (1) | WO2004048329A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049593A2 (en) * | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
| US8614318B2 (en) | 2003-11-13 | 2013-12-24 | Abbvie Inc. | Apoptosis promoters |
| US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
| US7767684B2 (en) | 2003-11-13 | 2010-08-03 | Abbott Laboratories | Apoptosis promoters |
| US8624027B2 (en) | 2005-05-12 | 2014-01-07 | Abbvie Inc. | Combination therapy for treating cancer and diagnostic assays for use therein |
| NZ561609A (en) | 2005-05-12 | 2010-03-26 | Abbott Lab | 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters |
| US7208526B2 (en) | 2005-05-20 | 2007-04-24 | Hoffmann-La Roche Inc. | Styrylsulfonamides |
| US7208506B2 (en) | 2005-07-07 | 2007-04-24 | Hoffmann-La Roche Inc. | Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents |
| WO2007054257A2 (en) * | 2005-11-08 | 2007-05-18 | Laboratorios Del Dr. Esteve, S.A. | Indene derivatives, their preparation and use as medicaments |
| US7625896B2 (en) | 2005-11-25 | 2009-12-01 | Hoffman-La Roche Inc. | Pyridylsulfonamide derivatives |
| US7939532B2 (en) | 2006-10-26 | 2011-05-10 | Hoffmann-La Roche Inc. | Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents |
| WO2009070744A1 (en) | 2007-11-28 | 2009-06-04 | Sequoia Pharmaceuticals, Inc. | Compositions and methods for inhibiting cytochrome p450 2d6 |
| CN101675033A (zh) | 2007-05-16 | 2010-03-17 | 霍夫曼-拉罗奇有限公司 | 芳基吡啶基磺酰胺衍生物，它们的制备和作为药剂的应用 |
| US8557983B2 (en) | 2008-12-04 | 2013-10-15 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20100160322A1 (en) | 2008-12-04 | 2010-06-24 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8563735B2 (en) | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| US8586754B2 (en) | 2008-12-05 | 2013-11-19 | Abbvie Inc. | BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| EP2550258B1 (de) * | 2010-03-25 | 2015-08-19 | Abbvie Inc. | Apoptoseinduktoren für die behandlung von krebs sowie immun- und autoimmunerkrankungen |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA941500B (en) | 1993-03-10 | 1995-09-04 | Lilly Co Eli | Antitumor compositions and methods of treatment |
| US5405727A (en) * | 1993-12-22 | 1995-04-11 | Eastman Kodak Company | N-(carbonyl, carbonimidoyl, carbonothioyl) sulfonamide charge control agents and toners and developers |
| BR0210078A (pt) | 2001-06-06 | 2004-06-22 | Lilly Co Eli | Composto, uso do mesmo, e, formulação farmacêutica |
-
2003
- 2003-11-13 AU AU2003290592A patent/AU2003290592A1/en not_active Abandoned
- 2003-11-13 ES ES03783127T patent/ES2294342T3/es not_active Expired - Lifetime
- 2003-11-13 US US10/535,002 patent/US7282595B2/en not_active Expired - Fee Related
- 2003-11-13 EP EP03783127A patent/EP1565438B1/de not_active Expired - Lifetime
- 2003-11-13 DE DE60316984T patent/DE60316984T2/de not_active Expired - Fee Related
- 2003-11-13 AT AT03783127T patent/ATE375978T1/de not_active IP Right Cessation
- 2003-11-13 WO PCT/US2003/035041 patent/WO2004048329A1/en not_active Ceased
-
2007
- 2007-09-11 US US11/853,158 patent/US20090118323A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003290592A1 (en) | 2004-06-18 |
| ES2294342T3 (es) | 2008-04-01 |
| US20060106053A1 (en) | 2006-05-18 |
| US7282595B2 (en) | 2007-10-16 |
| ATE375978T1 (de) | 2007-11-15 |
| WO2004048329A1 (en) | 2004-06-10 |
| EP1565438A1 (de) | 2005-08-24 |
| EP1565438B1 (de) | 2007-10-17 |
| DE60316984T2 (de) | 2008-07-17 |
| US20090118323A1 (en) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105386T1 (el) | Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου | |
| DE60230890D1 (de) | Indolizine als kinaseproteinhemmer | |
| ATE346070T1 (de) | Purinderivate als kinaseinhibitoren | |
| DE60310576D1 (en) | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer | |
| DE60316984D1 (de) | Benzoylsulfonamide als antitumor-mittel | |
| DE60313472D1 (de) | Pyrrolidindion-substituierte piperidin-phthalazone als pde4-inhibitoren | |
| ATE353217T1 (de) | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren | |
| CY1106132T1 (el) | Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου | |
| DE602004006433D1 (de) | Pyrrol-substituierte indole als inhibitoren von pai-1 | |
| CY1106247T1 (el) | Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες | |
| EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
| DE50208918D1 (de) | 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung | |
| SE0103710D0 (sv) | Compounds | |
| ATE419242T1 (de) | Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren | |
| ATE287403T1 (de) | 6-phenylbenzonaphthyidine | |
| ATE372330T1 (de) | N-sulfonylurea-apoptosis-förderer | |
| EA200600601A1 (ru) | Производные аминопиридина в качестве ингибиторов индуцируемой no-синтазы | |
| DE602004030231D1 (de) | Pyrimidinonverbindungen als calcilytica | |
| DE50311665D1 (de) | Guanidinophenylalanin-verbindungen als urokinase-inhibitoren | |
| ATE398617T1 (de) | Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase | |
| DK1521752T3 (da) | Makrocykliske forbindelser til behandling af cancer | |
| ATE508130T1 (de) | 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren | |
| DE60302222D1 (de) | Verbindungen zur verwendung als surfactanten | |
| ATE364037T1 (de) | Tryptasehemmer | |
| CY1110139T1 (el) | Γλυκοπεπτιδικα αντιβιοτικα |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8339 | Ceased/non-payment of the annual fee |